Source-grounded facts extracted from Replimune Group, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Replimune Group, Inc. amended credit facility with Hercules Capital, Inc. at greater of either (i) 8.50% and (ii) the Prime Rate (as defined in the Loan Agre.
“the interest rate was amended to be equal to the greater of either (i) 8.50% and (ii) the Prime Rate (as defined in the Loan Agreement) plus 1.75%, and the amortization date was extended from October 1, 2026 to October 1, 2027”
Replimune Group, Inc. incurred term loan of $35 million with Hercules Capital, Inc. at greater of either (i) 8.50% and (ii) the Prime Rate (as defined in the Loan Agre.
“the third loan tranche advance under the Loan Agreement was increased from $30 million to $35 million and the availability of the tranche was extended until June 15, 2026”
Replimune Group, Inc. amended Third Amendment to Loan and Security Agreement with Hercules Capital, Inc. valued at $35 million (effective 2026-01-29).
“On January 29, 2026 (the “Third Amendment Closing Date”), Replimune Group, Inc. (the “Company”) and certain subsidiaries of the Company (collectively, the “Borrowers”) entered into a Third Amendment to Loan and Security Agreement (the “Amendment”) with Hercules Capital, Inc. (“Hercules”), in its capacity as administrative agent and collateral agent (the “Agent”), and certain other financial institutions that from time to time may become parties to the Loan Agreement as lenders (collectively, the “Lenders”)”
Michael Goller was appointed as member of the Board at Replimune Group, Inc..
“appointed Michael Goller to the Board, effective immediately.”
Replimune Group, Inc. reported financial results for the fourth quarter and year ended March 31, 2024.
“Replimune Group, Inc. (the "Company") issued a news release announcing its financial results for the fourth quarter and year ended March 31, 2024”
Paul Bullock changed role as chief manufacturing officer at Replimune Group, Inc..
“Paul Bullock, the Company’s current senior vice president, operations and Framingham site head, is being promoted to the Company’s chief manufacturing officer effective April 1, 2024”
Tanya Lewis changed role as advisor at Replimune Group, Inc..
“Tanya Lewis, the Company’s current chief development operations officer, will leave their executive positions and plan to continue to lend their functional expertise in an advisory capacity”
Dr. Colin Love retired as chief operating officer at Replimune Group, Inc..
“Dr. Colin Love, the Company’s current chief operating officer, will retire from the Company, effective May 31, 2024”
Dieter Weinand changed role as lead independent director of the Board at Replimune Group, Inc..
“Dieter Weinand, the Company’s current chair of the Board, will transition into the newly created role of the lead independent director of the Board”
Philip Astley-Sparke changed role as executive chairman of the Board at Replimune Group, Inc..
“Philip Astley-Sparke, the Company’s current chief executive officer, will transition to the role of executive chairman of the Board”
Dr. Sushil Patel was appointed as chief executive officer at Replimune Group, Inc..
“Dr. Sushil Patel, the Company’s current chief strategy officer, has been appointed as the Company’s chief executive officer, effective as of April 1, 2024”
Replimune Group, Inc. reported financial results for third quarter ended December 31, 2023.
“On February 8, 2024, Replimune Group, Inc. (the “Company”) issued a news release announcing its financial results for the third quarter ended December 31, 2023 and certain corporate updates.”
Replimune Group, Inc. amended credit facility of the second loan tranche advance under the Loan Agreement was decreased from $45 million to $15 million, (ii) the third l with Hercules Capital, Inc..
“the revenue milestone date thereunder to July 31, 2026. In addition, pursuant to the Amendment, (i) the second loan tranche advance under the Loan Agreement was decreased from $45 million to $15 million, (ii) the third loan tranche advance under the Loan Agreement was increased from $25 million to $30 million and the availability of the tranche was extended until”
Replimune Group, Inc. amended Second Amendment to Loan and Security Agreement with Hercules Capital, Inc., as administrative agent and collateral agent, and certain other financial institutions as lenders (effective 2023-12-22).
“On December 22, 2023 (the “Closing Date”), Replimune Group, Inc. (the “Company”) and certain subsidiaries of the Company (collectively, the “Borrowers”) entered into a Second Amendment to Loan and Security Agreement (the “Amendment”) with Hercules Capital, Inc. (“Hercules”), in its capacity as administrative agent and collateral agent (the “Agent”), and certain other financial institutions that from time to time may become parties to the Loan Agreement as lenders (collectively, the “Lenders”) , pursuant to which the Company, Hercules, and the Lenders agreed to amend the Loan and Security Agreement dated October 6, 2022”
Replimune Group, Inc. reported financial results for fiscal second quarter ended September 30, 2023.
“Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced financial results for the fiscal second quarter ended September 30, 2023 and provided a business update.”
Emily Hill was appointed as Chief Financial Officer at Replimune Group, Inc..
“On September 19, 2023, Replimune Group, Inc. (“Replimune”) announced the appointment of Emily Hill as its Chief Financial Officer.”
Replimune Group, Inc. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm at the 2023-09-06 meeting.
“The selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending March 31, 2024, was ratified. Votes For Votes Against Votes Abstaining 51,869,761 4,084 5,375”
Replimune Group, Inc. shareholders approved Election of two Class II director nominees at the 2023-09-06 meeting.
“The following director nominees were elected to serve as Class II members of the Company’s board of directors, each to serve for a three-year term until the Company’s 2026 Annual Meeting of Stockholders and until his or her respective successor is duly elected and qualified: Nominee Votes For Votes Withheld Broker Non-Votes Paolo Pucci 25,146,894 21,307,605 5,424,721 Veleka Peeples-Dyer 43,195,979 3,258,520 5,424,721”
Replimune Group, Inc. reported financial results for fiscal first quarter ended June 30, 2023.
“On August 3, 2023, Replimune Group, Inc. (the “Company”) issued a news release announcing its financial results for the first quarter ended June 30, 2023”
Replimune Group, Inc. terminated 2022 Sales Agreement with Leerink Partners LLC valued at terminated (effective 2023-08-03).
“Pursuant to the Sales Agreement, the parties mutually agreed to terminate that certain sales agreement, dated June 23, 2022, by and between the Company and the Agent (as amended, the “2022 Sales Agreement”) with respect to the Company’s previous at-the-market offering program (the “2022 ATM Program”).”
Replimune Group, Inc. entered into Sales Agreement with Leerink Partners LLC valued at $250,000,000 (effective 2023-08-03).
“On August 3, 2023, Replimune Group, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (formerly known as SVB Securities LLC) (the “Agent”), pursuant to which the Company may sell, from time to time, at its option, up to an aggregate of $250.0 million of shares of the Company’s common stock, $0.001 par value per share (the “Shares”), through the Agent, as the Company’s sales agent.”
Sander Slootweg departed as Director at Replimune Group, Inc..
“On July 14, 2023, Sander Slootweg, a member of the Board of Directors (the “Board”) of Replimune Group, Inc. (the “Company”), notified the Board that he will not stand for reelection at the Company’s 2023 annual meeting of stockholders (the “Annual Meeting”), and therefore his service as a director of the Company will end at the conclusion of the Annual Meeting.”
Veleka Peeples-Dyer was appointed as Director at Replimune Group, Inc..
“On June 1, 2023, based on the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the "Board") of Replimune Group, Inc. (the "Company"), the Board appointed Veleka Peeples-Dyer to serve as a member of the Board, effective immediately.”
Replimune Group, Inc. reported financial results for the fourth quarter and year ended March 31, 2023.
“On May 18, 2023, Replimune Group, Inc. (the “Company”) issued a news release announcing its financial results for the fourth quarter and year ended March 31, 2023 and certain corporate updates.”
Andrew Schwendenman was appointed as Chief Accounting Officer at Replimune Group, Inc..
“the Board of Directors of the Company designated Andrew Schwendenman, the Company’s former Vice President of Finance, to serve as the Company’s Chief Accounting Officer effective as of May 18, 2023”
Jean Franchi resigned as Chief Financial Officer at Replimune Group, Inc..
“Jean Franchi has resigned from her position as the Company’s Chief Financial Officer, effective as of June 2, 2023”
Replimune Group, Inc. reported financial results for the fiscal third quarter ended December 31, 2022.
“On February 9, 2023, Replimune Group, Inc. issued a news release announcing its financial results for the third quarter ended December 31, 2022 and certain corporate updates.”
Replimune Group, Inc. reported financial results for second quarter ended September 30, 2022.
“On November 3, 2022, Replimune Group, Inc. issued a news release announcing its financial results for the second quarter ended September 30, 2022 and certain corporate updates.”
Jason Rhodes resigned as director at Replimune Group, Inc..
“On May 31, 2022, Jason Rhodes, a member of the Board of Directors (the “Board”) of Replimune Group, Inc. (the “Company”), notified the Board of his decision to resign as a director of the Company, effective immediately.”
Otello Stampacchia resigned as Director at Replimune Group, Inc..
“On January 26, 2022, Otello Stampacchia, Ph.D., a member of the Board of Directors (the “Board”) of Replimune Group, Inc. (the “Company”), notified the Board of his decision to resign as a director of the Company, effective immediately.”
Christy Oliger was appointed as Director at Replimune Group, Inc..
“the Board of Directors of the Company (the “ Board ”) increased the size of the Board from ten members to eleven and filled the newly created vacancy on the Board by appointing Christy Oliger as a director of the Company.”
Dr. Andrea Pirzkall was terminated as Chief Medical Officer at Replimune Group, Inc..
“Accordingly, on August 25, 2021, the Company notified Dr. Andrea Pirzkall that her employment with the Company has terminated, without cause.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.